Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bef580ac8e45156f710b77881eb90360f> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bef580ac8e45156f710b77881eb90360f NCIT_P378 "NCI" @default.
- Bef580ac8e45156f710b77881eb90360f type Axiom @default.
- Bef580ac8e45156f710b77881eb90360f annotatedProperty IAO_0000115 @default.
- Bef580ac8e45156f710b77881eb90360f annotatedSource NCIT_C180570 @default.
- Bef580ac8e45156f710b77881eb90360f annotatedTarget "A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing a short hairpin RNA (shRNA) against the pro-inflammatory cytokine interleukin-6 (IL-6), and linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunostimulating and antineoplastic activities. Upon administration, short hairpin RNA-IL-6 gene silencing anti-CD19 CAR T cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. IL-6 gene silencing reduces IL-6 gene expression and release. This may inhibit IL-6-mediated toxicity due to high IL-6 levels and may prevent severe cytokine release syndrome (CRS) and CAR-T-related encephalopathy (CRES)." @default.